```html

Hives (Chronic Urticaria) – Complete Medical Guide

Overview

Hives, medically known as urticaria, are red or skin‑colored welts that appear suddenly, itch intensely, and often disappear within 24 hours. When these lesions persist for six weeks or longer, the condition is termed **chronic urticaria**.

Chronic urticaria affects about 0.5–1 % of the global population and is more common in women (approximately 2:1 female‑to‑male ratio) and adults aged 20‑40 years, although children can be affected as well.<sup>[1] Mayo Clinic</sup>

While most cases are idiopathic (no identifiable cause), chronic urticaria can significantly impair quality of life because of relentless itching, sleep disruption, and anxiety about flare‑ups.

Symptoms

The hallmark of chronic urticaria is the appearance of wheals (hives) and/or angio‑edema (deep swelling). Typical symptoms include:

• Wheals (hives) – raised, well‑defined, pink to red plaques that blanch with pressure; usually < 1–3 cm in diameter but can coalesce into larger patches.
• Itching (pruritus) – often severe; scratching can worsen lesions.
• Burning or stinging sensation – reported by up to 30 % of patients.
• Angio‑edema – swelling of deeper skin layers, commonly around the lips, eyelids, tongue, or genital area; may last >24 h.
• Flare‑up pattern – lesions can appear anywhere on the body, often migrating every few hours.
• Nighttime worsening – itching may intensify at night, leading to insomnia.
• Systemic symptoms – rare, but may include headache, joint pain, or low‑grade fever.

Because each wheal typically resolves within 24 hours, chronic urticaria is defined by the *duration* of the disease rather than the persistence of individual lesions.

Causes and Risk Factors

In ~80 % of chronic urticaria cases the exact trigger is unknown (chronic idiopathic urticaria). When a cause can be identified, it generally falls into one of the following categories:

Autoimmune mechanisms

• Autoantibodies that target the high‑affinity IgE receptor (FcεRI) or IgE itself, causing mast‑cell degranulation.
• Associated with other autoimmune diseases (e.g., thyroiditis, lupus, celiac disease).

Allergic/IgE‑mediated triggers

• Food allergens (e.g., peanuts, shellfish) – more common in acute urticaria but can perpetuate chronic disease.
• Medications – especially NSAIDs, antibiotics, and ACE inhibitors.
• Physical stimuli – pressure, cold, heat, sunlight, water, vibration (physical urticarias).

Infections

• Helicobacter pylori, hepatitis C, Epstein‑Barr virus, and chronic sinusitis have been linked, though causality is not proven.

Other risk factors

• Female sex – hormonal influences may play a role.
• Age – peak incidence in the third to fourth decade.
• Stress – psychological stress can exacerbate flare‑ups.
• Chronic diseases – e.g., thyroid disease, rheumatoid arthritis.

Diagnosis

Diagnosis is primarily clinical, based on history and physical examination. The physician will:

1. Document duration of symptoms (>6 weeks).
2. Identify lesion characteristics (size, shape, blanchability).
3. Rule out mimickers (e.g., eczema, drug eruptions, vasculitis).

Laboratory and specialty tests

Routine labs are often normal, but targeted testing can uncover an underlying cause:

• Complete blood count (CBC) – looks for eosinophilia.
• Thyroid function tests (TSH, free T4) and anti‑thyroid antibodies – thyroid autoimmunity is present in ~10‑20 % of patients.<sup>[2] Cleveland Clinic</sup>
• Autoimmune work‑up – ANA, rheumatoid factor if clinical suspicion.
• Specific IgE or skin prick testing – if an allergic trigger is suspected.
• Physical challenge tests – e.g., ice cube test for cold urticaria, dermographism test for pressure urticaria.
• Biopsy – rarely needed, used to rule out urticarial vasculitis (shows vessel inflammation).

Diagnostic criteria (International EAACI/GA²LEN/EDF/WAO guideline)

• Recurrent wheals/angio‑edema for ≥6 weeks.
• Each individual lesion lasts <24 h (except for angio‑edema).
• No evidence of other dermatoses that better explain the presentation.

Treatment Options

Treatment aims to control itching, reduce wheal frequency, and improve quality of life. Management follows a stepwise approach.

1. Non‑pharmacologic measures

• Avoid known triggers (e.g., NSAIDs, extreme temperatures).
• Wear loose, breathable clothing; use mild, fragrance‑free skin care products.
• Apply cool compresses to relieve acute itch.

2. First‑line medication: Second‑generation antihistamines

These are preferred due to less sedation and fewer anticholinergic effects.

Drug	Typical dose	Notes
Cetirizine	10 mg once daily (may increase to 20 mg)	May cause mild drowsiness in some.
Levocetirizine	5 mg once daily	Highly selective, low sedation.
Loratadine	10 mg once daily (max 20 mg)	Very low CNS penetration.
Fexofenadine	180 mg once daily (max 360 mg)	Safe in pregnancy (Category B).
Desloratadine	5 mg once daily	Often effective in refractory cases.

If standard dosing fails after 2‑4 weeks, guidelines permit up‑titration up to four times the usual dose.

3. Second‑line agents

• H₁ antihistamine + H₂ blocker (e.g., cetirizine + ranitidine) – modest benefit.
• Leukotriene receptor antagonists (e.g., montelukast 10 mg nightly) – add‑on for NSAID‑triggered urticaria.
• Systemic corticosteroids – short courses (≤10 days) for severe flares; not for long‑term use due to side effects.

4. Third‑line (biologic) therapy

For patients uncontrolled after high‑dose antihistamines and add‑ons, omalizumab (anti‑IgE monoclonal antibody) is the preferred biologic.

• Dosage: 300 mg subcutaneous injection every 4 weeks.
• Response rates: 60‑80 % achieve symptom control within 12 weeks.<sup>[3] NIH</sup>
• Generally well‑tolerated; rare anaphylaxis (<0.1 %).

5. Other immunomodulators (reserved for refractory cases)

• Ciclosporin – 3‑5 mg/kg/day; monitor renal function and blood pressure.
• Methotrexate or mycophenolate mofetil – limited data, used by specialists.

6. Procedural options

• Phototherapy (PUVA) – occasional benefit, requires dermatology referral.
• Plasma exchange – experimental, used only in severe autoimmune urticaria.

Living with Hives (Chronic Urticaria)

Chronic urticaria can be frustrating, but many patients regain control with proper treatment and lifestyle tweaks.

Daily management tips

• Medication adherence – take antihistamines at the same time each day; keep a pill organizer.
• Symptom diary – record wheal onset, possible triggers, stress levels, and medication response. This aids your clinician in tailoring therapy.
• Skin care – use lukewarm water for showers, limit bathing to ≤10 minutes, and pat skin dry.
• Cool compresses – apply a damp, cool cloth for 5‑10 minutes during acute itch.
• Stress management – yoga, meditation, or counseling can reduce flare frequency.
• Sleep hygiene – keep bedroom cool (18‑20 °C), use breathable bedding, and avoid late‑night caffeine.
• Vaccinations – generally safe; inform the provider of your antihistamine regimen.
• Travel prep – bring an extra supply of antihistamines, a short course of oral steroids (if prescribed), and a note from your physician.

Psychosocial support

Approximately 30‑40 % of chronic urticaria patients report anxiety or depression. Consider:

• Connecting with support groups (online forums, local allergy societies).
• Seeking counseling or cognitive‑behavioral therapy.
• Discussing mood changes with your clinician—sometimes adjusting medication can improve both skin and mental health.

Prevention

While idiopathic chronic urticaria cannot be entirely prevented, you can lower the risk of flares by:

• Identifying and avoiding personal triggers – keep a trigger log.
• Limiting NSAID use – choose acetaminophen when appropriate.
• Maintaining a balanced diet – some studies suggest that a low‑histamine diet may help, although evidence is mixed.
• Staying hydrated – adequate fluids may reduce skin irritability.
• Managing thyroid disease or other autoimmune conditions – regular follow‑up labs.
• Practicing good skin hygiene – avoid harsh soaps, detergents, and scented products.

Complications

If left inadequately treated, chronic urticaria can lead to:

• Sleep disturbance – chronic insomnia, daytime fatigue.
• Psychological distress – anxiety, depression, reduced work productivity.
• Secondary skin changes – excoriation, hyperpigmentation, or lichenification from chronic scratching.
• Angio‑edema of the airway – rare but potentially life‑threatening; more common in patients with concomitant allergic disease.
• Medication side effects – especially with long‑term systemic steroids or immunosuppressants.

When to Seek Emergency Care

---

References

1. Mayo Clinic. Chronic urticaria: Symptoms & causes. https://www.mayoclinic.org
2. Cleveland Clinic. Chronic urticaria: Diagnosis and treatment. https://my.clevelandclinic.org
3. National Institutes of Health (NIH). Omalizumab for chronic spontaneous urticaria. https://www.ncbi.nlm.nih.gov

```